Engy › Who's who in longevity › Jeffrey Cummings
At a glance
- Neurologist and professor at the Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas (UNLV), where he leads the Chambers-Grundy Center for Transformative Neuroscience.
- Was previously founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas.
- Developed the Neuropsychiatric Inventory (1994), a widely used questionnaire for measuring behavioural and mood symptoms in dementia.
- Publishes an annual overview of every Alzheimer’s drug being tested in clinical trials — a reference for researchers and policymakers.
- Wrote in 2026 about the lessons from the evoke trials of semaglutide in early Alzheimer’s, and about current symptomatic treatments.
- Relevant because he offers a clear view of where drug development against dementia stands — a useful counterweight to hopeful headlines.
Criticism and nuance
Advises many pharmaceutical companies developing Alzheimer’s drugs, which he discloses in his publications.
Recent
- Study Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications
- Study Symptomatic treatment for Alzheimer disease: current evidence and future directions
- Study Cognitive, biomarker, and neuroimaging indices associated with traumatic encephalopathy syndrome across two independent athlete cohorts
- Study Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease
- Study Alzheimer's disease drug development pipeline: 2026